Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at Stifel Nicolaus

Analysts at Stifel Nicolaus started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 78.41% from the company’s previous close.

Several other equities research analysts also recently commented on the stock. HC Wainwright upped their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Guggenheim started coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price for the company. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. The Goldman Sachs Group upped their target price on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Mizuho upped their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.50.

Enliven Therapeutics Price Performance

ELVN opened at $33.63 on Tuesday. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -20.14 and a beta of 0.29. The firm has a 50 day simple moving average of $41.32 and a 200 day simple moving average of $30.28. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, analysts expect that Enliven Therapeutics will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. Vestal Point Capital LP increased its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares in the last quarter. Siren L.L.C. bought a new stake in shares of Enliven Therapeutics during the first quarter worth $29,252,000. Affinity Asset Advisors LLC bought a new stake in shares of Enliven Therapeutics during the first quarter worth $23,007,000. TCG Crossover Management LLC bought a new stake in shares of Enliven Therapeutics during the second quarter worth $9,990,000. Finally, Duquesne Family Office LLC increased its position in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.